Sarepta Therapeutics Inc (NASDAQ:SRPT) Director M Kathleen Behrens Acquires 2,500 Shares

Sarepta Therapeutics Inc (NASDAQ:SRPT) Director M Kathleen Behrens bought 2,500 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was acquired at an average price of $87.98 per share, for a total transaction of $219,950.00. Following the acquisition, the director now directly owns 123,167 shares in the company, valued at $10,836,232.66. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

SRPT stock traded down $3.26 during trading on Friday, reaching $85.76. The stock had a trading volume of 77,960 shares, compared to its average volume of 2,462,157. Sarepta Therapeutics Inc has a one year low of $85.70 and a one year high of $165.87. The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $123.25 and its two-hundred day moving average is $127.29. The company has a market capitalization of $6.40 billion, a price-to-earnings ratio of -15.67 and a beta of 2.19.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The firm had revenue of $94.67 million during the quarter, compared to the consensus estimate of $91.05 million. During the same period in the previous year, the company posted ($1.67) earnings per share. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. As a group, research analysts predict that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on the stock. Robert W. Baird lowered their target price on shares of Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating on the stock in a report on Tuesday, August 20th. Royal Bank of Canada lowered their target price on shares of Sarepta Therapeutics to $204.00 and set an “outperform” rating on the stock in a report on Tuesday, August 20th. Evercore ISI restated a “buy” rating and issued a $200.00 target price on shares of Sarepta Therapeutics in a report on Thursday, August 8th. Cantor Fitzgerald lowered their target price on shares of Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating on the stock in a report on Tuesday, August 20th. Finally, ValuEngine upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $197.78.

A number of hedge funds have recently modified their holdings of SRPT. International Biotechnology Trust PLC boosted its holdings in Sarepta Therapeutics by 89.1% in the 2nd quarter. International Biotechnology Trust PLC now owns 26,100 shares of the biotechnology company’s stock worth $3,965,000 after buying an additional 12,300 shares during the period. UBS Group AG grew its position in shares of Sarepta Therapeutics by 36.0% during the second quarter. UBS Group AG now owns 109,361 shares of the biotechnology company’s stock worth $16,617,000 after buying an additional 28,958 shares in the last quarter. Walleye Trading Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $1,688,000. Amundi Pioneer Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 26.0% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 194,845 shares of the biotechnology company’s stock worth $29,607,000 after buying an additional 40,234 shares in the last quarter. Finally, Voleon Capital Management LP acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $5,166,000. 93.59% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Read More: Trading signals using Bollinger bands

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.